FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:759-762 March 8, 2001 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Bernard, G. R. PubMed Citation

In the last half of the 20th century, the use of antibiotics for the treatment of bacterial infections transformed the practice of medicine, resulting in sharp reductions in morbidity and mortality from acute and chronic infections. However, mortality has remained high when an acute bacterial infection induces sepsis with shock, metabolic acidosis, oliguria, or hypoxemia. In fact, in the United States alone, there are at least 500,000 episodes of sepsis annually, and the resultant mortality rate ranges from 30 to 50 percent, even with intensive medical care, including antibiotics, intravenous fluids, nutrition, mechanical ventilation for respiratory failure, and surgery when . . . [Full Text of this Article]

References

This article has been cited by other articles:

• (2008). ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems. Am J Health Syst Pharm 65: 1368-1384 [Full Text]  
• Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., Uchiyama, J., Sakurai, S., Matsuzaki, S., Imai, S., Yamaguchi, K. (2007). Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice. Antimicrob. Agents Chemother. 51: 446-452 [Abstract] [Full Text]  
• Liang, H. (2006). Checking linearity of non-parametric component in partially linear models with an application in systemic inflammatory response syndrome study. Stat Methods Med Res 15: 273-284 [Abstract]  
• Hoots, W. K. (2006). Challenges in the Therapeutic Use of a "So-Called" Universal Hemostatic Agent: Recombinant Factor VIIa. ASH Education Book 2006: 426-431 [Abstract] [Full Text]  
• Abraham, E. (2005). Effects of Recombinant Human Activated Protein C in Human Models of Endotoxin Administration. Proc Am Thorac Soc 2: 243-247 [Abstract] [Full Text]  
• Knaus, W. A. (2005). Designing Trials and Deciding on Therapy in Complex Diseases: What Can We Do to Improve?. Med Decis Making 25: 366-369  
• Jacobson, J. R., Barnard, J. W., Grigoryev, D. N., Ma, S.-F., Tuder, R. M., Garcia, J. G. N. (2005). Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 288: L1026-L1032 [Abstract] [Full Text]  
• Bridges, E. J., Dukes, S. (2005). Cardiovascular Aspects of Septic Shock: Pathophysiology, Monitoring, and Treatment. Crit Care Nurse 25: 14-40 [Full Text]  
• Ahamed, J., Belting, M., Ruf, W. (2005). Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 105: 2384-2391 [Abstract] [Full Text]  
• Tazbir, J. (2004). Sepsis and the Role of Activated Protein C. Crit Care Nurse 24: 40-45 [Full Text]  
• Paria, B. C., Vogel, S. M., Ahmmed, G. U., Alamgir, S., Shroff, J., Malik, A. B., Tiruppathi, C. (2004). Tumor necrosis factor-{alpha}-induced TRPC1 expression amplifies store-operated Ca2+ influx and endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 287: L1303-L1313 [Abstract] [Full Text]  
• Burry, L. D, Wax, R. S (2004). Role of Corticosteroids in Septic Shock. The Annals of Pharmacotherapy 38: 464-472 [Abstract] [Full Text]  
• (2003). Minerva. BMJ 327: E36-36 [Full Text]  
• Kleinpell, R. (2003). Advances in Treating Patients With Severe Sepsis: Role of Drotrecogin Alfa (Activated). Crit Care Nurse 23: 16-29 [Full Text]  
• Kvalsvig, A J, Unsworth, D J (2003). The immunopathogenesis of meningococcal disease. J. Clin. Pathol. 56: 417-422 [Abstract] [Full Text]  
• Hotchkiss, R. S., Karl, I. E. (2003). The Pathophysiology and Treatment of Sepsis. NEJM 348: 138-150 [Full Text]  
• Pastores, S M (2003). Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Postgrad. Med. J. 79: 5-10 [Abstract] [Full Text]  
• Matthay, M. A., Folkesson, H. G., Clerici, C. (2002). Lung Epithelial Fluid Transport and the Resolution of Pulmonary Edema. Physiol. Rev. 82: 569-600 [Abstract] [Full Text]  
• Atabai, K, Matthay, M A (2002). The pulmonary physician in critical care * 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology. Thorax 57: 452-458 [Abstract] [Full Text]  
• (2001). Drotrecogin Alfa (Activated): A New Treatment for Severe Sepsis. JWatch Infect. Diseases 2001: 3-3 [Full Text]  
• Brower, R. G., Ware, L. B., Berthiaume, Y., Matthay, M. A. (2001). Treatment of ARDS. Chest 120: 1347-1367 [Abstract] [Full Text]  
• Greisman, S. E., Johnston, C. A., Gosnell, M. S., Kapur, S., Kupfer, Y., Tessler, S., Ott, A., Verbrugh, H. A., O'Connor, P. E., Bernard, G. R., Ely, E. W., Helterbrand, J. D. (2001). Recombinant Human Activated Protein C for Severe Sepsis. NEJM 345: 219-221 [Full Text]  
• Calfee, J. E. (2001). Pharmaceutical Price Controls and Patient Welfare. ANN INTERN MED 134: 1060-1064 [Abstract] [Full Text]  
• (2001). Finally, an Effective New Treatment for Severe Sepsis?. JWatch Gastroenterology 2001: 12-12 [Full Text]  
• (2001). Finally, an Effective New Treatment for Severe Sepsis?. JWatch General 2001: 1-1 [Full Text]  
• (2001). Finally, Effective Therapy for Sepsis. JWatch Infect. Diseases 2001: 2-2 [Full Text]